SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Cassava Sciences has announced plans to extend trials for its Alzheimer’s treatment drug. This news isn't helping SAVA stock.
The post SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months appeared first on InvestorPlace.
More From InvestorPlace